Astria Therapeutics Announces Positive Results from ALPHA-SOLAR Trial, Highlighting Navenibart's Potential as a Market-Leading Treatment for Hereditary Angioedema

Reuters

2025/06/13

Astria <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Results from ALPHA-SOLAR Trial, Highlighting Navenibart's Potential as a Market-Leading Treatment for Hereditary Angioedema

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on therapies for allergic and immunologic diseases, has announced positive initial results from its ALPHA-SOLAR long-term open-label trial. The trial evaluates navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema $(HAE)$ patients. The results showed a 95% mean monthly attack-rate reduction in the Q3M arm and an 86% reduction in the Q6M arm, demonstrating the drug's favorable safety profile. These findings were presented at the European Academy of Allergy and Clinical Immunology Annual Congress on June 13, 2025. Astria has also initiated the pivotal Phase 3 ALPHA-ORBIT trial, which is currently enrolling patients to further evaluate navenibart's efficacy and safety.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613335891) on June 13, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2543368628"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543368628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543368628?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543368628","market":"nz","top_or_hot":-1,"title":"Astria Therapeutics Announces Positive Results from ALPHA-SOLAR Trial, Highlighting Navenibart's Potential as a Market-Leading Treatment for Hereditary Angioedema","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Results from ALPHA-SOLAR Trial, Highlighting Navenibart's Potential as a Market-Leading Treatment for Hereditary Angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on therapies for allergic and immunologic diseases, has announced positive initial results from its ALPHA-SOLAR long-term open-label trial. The trial evaluates navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> patients. The results showed a 95% mean monthly attack-rate reduction in the Q3M arm and an 86% reduction in the Q6M arm, demonstrating the drug's favorable safety profile. These findings were presented at the European Academy of Allergy and Clinical Immunology Annual Congress on June 13, 2025. Astria has also initiated the pivotal Phase 3 ALPHA-ORBIT trial, which is currently enrolling patients to further evaluate navenibart's efficacy and safety.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ATXS\">Astria Therapeutics Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613335891) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astria Therapeutics Announces Positive Results from ALPHA-SOLAR Trial, Highlighting Navenibart's Potential as a Market-Leading Treatment for Hereditary Angioedema</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstria Therapeutics Announces Positive Results from ALPHA-SOLAR Trial, Highlighting Navenibart's Potential as a Market-Leading Treatment for Hereditary Angioedema\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-13 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Results from ALPHA-SOLAR Trial, Highlighting Navenibart's Potential as a Market-Leading Treatment for Hereditary Angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on therapies for allergic and immunologic diseases, has announced positive initial results from its ALPHA-SOLAR long-term open-label trial. The trial evaluates navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> patients. The results showed a 95% mean monthly attack-rate reduction in the Q3M arm and an 86% reduction in the Q6M arm, demonstrating the drug's favorable safety profile. These findings were presented at the European Academy of Allergy and Clinical Immunology Annual Congress on June 13, 2025. Astria has also initiated the pivotal Phase 3 ALPHA-ORBIT trial, which is currently enrolling patients to further evaluate navenibart's efficacy and safety.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ATXS\">Astria Therapeutics Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613335891) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATXS","symbol_name":"Astria Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL6VMwsy:1","article_id":"2543368628","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543368628","pubTimestamp":1749812429,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Astria Therapeutics Announces Positive Results from ALPHA-SOLAR Trial, Highlighting Navenibart's Potential as a Market-Leading Treatment for Hereditary Angioedema. Astria Therapeutics, Inc. , a biopharmaceutical company focused on therapies for allergic and immunologic diseases, has announced positive initial results from its ALPHA-SOLAR long-term open-label trial. The trial evaluates navenibart , a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema  patients. The results showed a 95% mean monthly attack-rate reduction in the Q3M arm and an 86% reduction in the Q6M arm, demonstrating the drug's favorable safety profile. These findings were presented at the European Academy of Allergy and Clinical Immunology Annual Congress on June 13, 2025. Astria has also initiated the pivotal Phase 3 ALPHA-ORBIT trial, which is currently enrolling patients to further evaluate navenibart's efficacy and safety.Disclaimer: This news brief was created by Public Technologies  usi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATXS":"Astria Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Astria Therapeutics宣布ALPHA-SOLAR试验的积极结果，凸显了Navenibart作为遗传性血管性水肿市场领先治疗方法的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATXS":0.9},"content_text":"Astria Therapeutics Announces Positive Results from ALPHA-SOLAR Trial, Highlighting Navenibart's Potential as a Market-Leading Treatment for Hereditary Angioedema\n    \n\n        Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on therapies for allergic and immunologic diseases, has announced positive initial results from its ALPHA-SOLAR long-term open-label trial. The trial evaluates navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema $(HAE)$ patients. The results showed a 95% mean monthly attack-rate reduction in the Q3M arm and an 86% reduction in the Q6M arm, demonstrating the drug's favorable safety profile. These findings were presented at the European Academy of Allergy and Clinical Immunology Annual Congress on June 13, 2025. Astria has also initiated the pivotal Phase 3 ALPHA-ORBIT trial, which is currently enrolling patients to further evaluate navenibart's efficacy and safety.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250613335891) on June 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}